Our Mission is to improve the lives of patients suffering from difficult to treat cancers, with a focus on pancreatic cancer through novel therapies that prime and boost their immune response and improve the performance of their cancer treatment, enabling them to live longer.
Immodulon is a private, late-stage clinical company developing IMM-101, a novel broad spectrum immunomodulator. IMM-101 induces a broad immune response, modulating the innate and adaptive immune systems with a potential to complement existing therapies, including targeted immunotherapies and cytotoxics. IMM-101 has the potential to work in difficult-to-treat tumours, including those that have been considered immunologically ‘cold’.
Immodulon has generated promising phase II data with IMM-101 in first line patients with advanced pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine.
Latest from Immodulon
Immodulon Appoints New Chair and Leadership Team to Drive Late-Stage Clinical Development of IMM-101 in Pancreatic Cancer
Richard Davies, Deputy Chairman of Alvotech, elected as Chairman of the Board Gertjan Bartlema, formerly at Celgene and Amgen, appointed as Chief Executive Officer Peter Greaney, formerly at ADC Therapeutics and Celgene, appointed as Chief Business Officer...
Immodulon strengthens Board of Directors with two industry veteran appointments
Seasoned global biopharmaceutical executives add significant clinical and commercial experience to Immodulon Dr. Selwyn Ho and Gertjan Bartlema will join the Board with immediate effect Uxbridge, UK – 14 June 2022 – Immodulon Therapeutics Limited, the immuno-oncology...
Immodulon presents Phase II clinical data of IMM-101 in combination with checkpoint inhibitors in patients with advanced melanoma at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
IMM-101 in combination with nivolumab was well-tolerated and demonstrated encouraging efficacy data Primary endpoints were met, including 73% Overall Response Rate (ORR) in treatment-naïve patients with advanced melanoma Uxbridge, UK, 7 June 2022 – Immodulon...